Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05176470
Title Lifileucel and Pembrolizumab for the Treatment of Locally Advanced Stage IIIB-D Melanoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Richard Wu
Indications

melanoma

Therapies

Cyclophosphamide + Fludarabine + LN-144 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.